Determination of Mitotane (DDD) and Principal Metabolite by a Simple HPLC-UV Method and Its Validation in Human Plasma Samples
Mitotane (DDD) is prescribed in adrenocortical renal carcinoma. Its principal metabolite, dichlorodiphenylethene (DDE), can accumulate in fat tissues and from a toxicological point of view, is probably more interesting than the other metabolite dichlorodiphenylacetate (DDA). Therapeutic Drug Monitor...
Main Authors: | Giacomo Luci, Federico Cucchiara, Laura Ciofi, Francesca Mattioli, Marianna Lastella, Romano Danesi, Antonello Di Paolo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Separations |
Subjects: | |
Online Access: | https://www.mdpi.com/2297-8739/8/5/63 |
Similar Items
-
Clinical results of the use of mitotane for adrenocortical carcinoma
by: A.A. Kasperlik-Zaluska
Published: (2000-10-01) -
Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
by: Nadia Gagnon, et al.
Published: (2023-01-01) -
Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog
by: Su‐Min Park, et al.
Published: (2021-07-01) -
Precocious puberty and other endocrine disorders during mitotane treatment for paediatric adrenocortical carcinoma – case series and literature review
by: Elżbieta Moszczyńska, et al.
Published: (2024-02-01) -
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
by: Antonina Germano, et al.
Published: (2020-04-01)